“The results of this Phase 2a clinical trial of SBI-100 OE unfortunately did not meet our pre-set criteria for continuation and further development of this molecule as an alternative treatment for glaucoma and ocular hypertension. We will continue to evaluate the full data set and intend to publish findings,” said Tu Diep, Skye‘s Chief Development Officer. “We thank the patients and investigators who supported our clinical investigation of SBI-100 OE in this study.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SKYE:
- Skye Bioscience to Present at Jefferies Global Healthcare Conference
- Skye Bioscience initiated with an Overweight at Cantor on obesity opportunity
- Skye Bioscience initiated with an Overweight at Cantor Fitzgerald
- Three new option listings on May 22nd
- Skye Bioscience announces presentation of poster on dry eye disease at ARVO 2024